NCT04793815View on ClinicalTrials.gov

Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

June 27, 2023

Study Completion Date

June 27, 2023

Conditions
Non-small Cell Lung Cancer MetastaticCryotherapy Effect
Interventions
PROCEDURE

Cryo-activation

The cryo-activation procedure involves the insertion of a cryoprobe in the tumor bed with subsequent application of very low temperatures leading to cell necrosis and tumor antigens release.

DRUG

Pembrolizumab

Following the cryo-activation procedure, patients will sequentially be treated with pembrolizumab (anti-PD-1) monotherapy.

Trial Locations (1)

H2X 3E4

Centre hospitalier de l'Université de Montréal (CHUM), Montreal

All Listed Sponsors
lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER